Pharmaceuticals Malaysia

Malaysia Exosome Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Malaysia Exosome Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Application, Source, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Malaysia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $0.5 Mn Placeholder estimate
Estimate 2025 $0.6 Mn 0.2% of the global market
Projected 2034 $4.7 Mn 650.4% Adds $4.1 Mn over 9 forecast years
CAGR 2025–2034 25.1% Faster than 95% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Malaysia is 0.2% of the global market.
  • In APAC, the largest is China at $26.9 Mn.
  • Fastest growing: India at 28.2% a year.
  • Malaysia ranks 7th of 10 by size in APAC.

Market size projection

Malaysia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$4.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Exosome Therapeutics Market market size by year, Malaysia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $0.5 Mn — —
2025 (base) $0.6 Mn +$0.1 Mn —
2026 (forecast) $0.8 Mn +$0.2 Mn +25.1%
2027 (forecast) $1.0 Mn +$0.2 Mn +56.5%
2028 (forecast) $1.2 Mn +$0.2 Mn +95.8%
2029 (forecast) $1.5 Mn +$0.3 Mn +144.9%
2030 (forecast) $1.9 Mn +$0.4 Mn +206.4%
2031 (forecast) $2.4 Mn +$0.5 Mn +283.3%
2032 (forecast) $3.0 Mn +$0.6 Mn +379.5%
2033 (forecast) $3.8 Mn +$0.8 Mn +499.9%
2034 (forecast) $4.7 Mn +$0.9 Mn +650.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $312.5 Mn
  2. North America $152.8 Mn
  3. US $138.3 Mn
  4. APAC $65.6 Mn
  5. Europe $59.7 Mn
  6. Canada $28.2 Mn
  7. China $26.9 Mn
  8. Japan $21.1 Mn
  9. Latin America $14.7 Mn
  10. Middle East $12.9 Mn
  11. Germany $12.1 Mn
  12. UK $8.2 Mn
  13. Brazil $7.7 Mn
  14. Italy $7.6 Mn
  15. France $7.2 Mn
  16. Spain $6.6 Mn
  17. Ecuador $5.5 Mn
  18. India $5.8 Mn
  19. Mexico $5.2 Mn
  20. Saudi Arabia $5.1 Mn
  21. Africa $4.2 Mn
  22. Australia $4.0 Mn
  23. New Zealand $3.7 Mn
  24. Russia $3.1 Mn
  25. South Africa $1.9 Mn
  26. UAE $1.6 Mn
  27. Egypt $1.0 Mn
  28. Malaysia (this report) $0.6 Mn
  29. Philippines $0.6 Mn
  30. Hong Kong $0.5 Mn
  31. Singapore $0.5 Mn
  32. Thailand $0.5 Mn
  33. Kenya $0.2 Mn

Report snapshot

Malaysia Exosome Therapeutics Market Analysis at a glance
Market size, 2025$0.6 Mn placeholder estimate
Forecast, 2034$4.7 Mn placeholder estimate
Growth (CAGR), 2025–203425.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsApplication, source and end user (see all)
Key playersCodiak BioSciences, Evox Therapeutics, Aegle Therapeutics, Capricor Therapeutics, ExoCoBio, Inc (see all)
Regulator in MalaysiaNPRASource: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Malaysia Exosome Therapeutics Market Analysis Executive Summary

Exosome therapeutics use tiny vesicles released by cells to carry drugs or healing signals, for cancer, inflammation and regenerative medicine.

Key segments of the exosome Therapeutics market include application (Drug Delivery, Regenerative Medicine and Diagnostics) and source (Stem Cell-Derived, Plant-Derived and Engineered).

Bar chart: Malaysia Exosome Therapeutics market size, 2024–2034, placeholder estimates. $0.5 Mn in 2024, $0.6 Mn in 2025 and $4.7 Mn in 2034, 25.1% CAGR.
Malaysia Exosome Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Malaysia Exosome Therapeutics Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the exosome Therapeutics market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the exosome Therapeutics market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the exosome Therapeutics market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Exosome Therapeutics Market in Malaysia

The exosome Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Exosome Therapeutics Market in Malaysia

Exosome Therapeutics in Malaysia: rules and payment

Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA).⁠[1] Public clinics and hospitals run by the Ministry of Health give heavily subsidised care.⁠[2]

[1] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[2] Ministry of Health Malaysia. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for exosome Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Malaysia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Exosome Therapeutics right now, from free public sources.

Latest research 29 papers since 2021 (worldwide)

  1. Combination of kale-derived exosomes and dactolisib promotes apoptosis and modulates iron homeostasis in Hep3B hepatocellular carcinoma cells. Molecular biology reports, 2026
  2. Exosomal innovations in neurodegenerative disorders: Emerging insights and intranasal route. Biochemical and biophysical research communications, 2026
  3. An Innovative Strategy for Treating Neurodegenerative Disorders through Exosome-based Smart Delivery Systems: A Comprehensive Review. CNS & neurological disorders drug targets, 2026
  4. Biomaterial Engineering for Spatiotemporal Regulation of Exosome Functions: From Design Principles to Key Applications in Regenerative Medicine. Pharmaceuticals (Basel, Switzerland), 2026
  5. Engineering cardiac regeneration using stem cells: Cellular sources, differentiation signatures, targeted delivery, and functional recovery. Regenerative therapy, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Exosome Therapeutics in context

Malaysia compared

  • Health spending per person: 450 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.34 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 6th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 8.0% of people (2025). World: 10.4% of people (2025). 8th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Exosome Therapeutics market in Malaysia?
Placeholder estimate: about $0.6 Mn in 2025, rising to about $4.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Exosome Therapeutics market in Malaysia growing?
Placeholder estimate: about 25.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Exosome Therapeutics market report cover?
The report splits the market by application (Drug Delivery, Regenerative Medicine, Diagnostics, Oncology), source (Stem Cell-Derived, Plant-Derived, Engineered) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Exosome Therapeutics market?
Key players include Codiak BioSciences, Evox Therapeutics, Aegle Therapeutics, Capricor Therapeutics and ExoCoBio, Inc.
What is driving the Exosome Therapeutics market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the exosome Therapeutics market.
Who regulates Exosome Therapeutics in Malaysia?
Medicines must be registered with the Drug Control Authority, which works through the National Pharmaceutical Regulatory Agency (NPRA). Source: National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in Malaysia?
Public clinics and hospitals run by the Ministry of Health give heavily subsidised care. Source: Ministry of Health Malaysia. Checked 14 Nov 2026.
How much research is published on Exosome Therapeutics?
PubMed lists 29 papers on Exosome Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Exosome Therapeutics in Malaysia? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Malaysia

See all
Same topic, other categories

Related on biologics and biosimilars and genomics

See the topic